Exciting News from Palisade Bio, Inc.

Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) —

Palisade Bio, Inc. (Nasdaq: PALI): Advancing Therapeutics for Autoimmune Diseases

Palisade Bio, Inc., a leading clinical-stage biopharmaceutical company, has announced a major milestone in its quest to develop novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases. The company’s abstract has been accepted for a poster presentation at the prestigious Crohn’s & Colitis Congress, scheduled to take place from February 6-8, 2025, in San Francisco, CA.

This is a significant recognition of Palisade Bio’s efforts to advance cutting-edge treatments for individuals living with chronic conditions such as Crohn’s disease and ulcerative colitis. The Company’s commitment to improving the lives of patients through innovative research and development is commendable.

Attendees at the Crohn’s & Colitis Congress will have the opportunity to learn more about Palisade Bio’s groundbreaking work and the potential impact of its therapies on the field of autoimmune diseases. The poster presentation is a platform for the Company to share its latest findings and engage with key stakeholders in the medical community.

Impact on Individuals:

For patients living with autoimmune diseases like Crohn’s and colitis, this news represents a glimmer of hope for more effective treatment options. Palisade Bio’s focus on developing therapeutics tailored to these conditions could potentially transform the way these diseases are managed, offering patients a better quality of life and improved outcomes.

Global Implications:

Palisade Bio’s innovative approach to tackling autoimmune, inflammatory, and fibrotic diseases has the potential to make a significant impact on the global healthcare landscape. By pushing the boundaries of scientific research and bringing novel therapies to the market, the Company is contributing to the advancement of medical science and the betterment of patient care worldwide.

Conclusion:

Palisade Bio’s acceptance at the Crohn’s & Colitis Congress is a testament to the company’s dedication to improving the lives of individuals with autoimmune diseases. As we look ahead to the poster presentation in San Francisco, we anticipate further insights that could pave the way for transformative treatments in the field of autoimmune, inflammatory, and fibrotic diseases. Stay tuned for more updates on Palisade Bio’s pioneering work and its potential impact on patients and the global healthcare community.